ARS Pharmaceuticals, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Theravance Biopharma, Inc.

Liquidia Corp.

Marinus Pharmaceuticals, Inc.

SIGA Technologies, Inc.

Aclaris Therapeutics, Inc.

Zymeworks, Inc.

ARS Pharmaceuticals, Inc.

Savara, Inc.

Oculis Holding AG

Biomea Fusion, Inc.

Procaps Group SA

Why is ARS Pharmaceuticals, Inc. ?

The company has declared negative results for the last 4 consecutive quarters

The company has declared negative results in Jun 25 after 2 consecutive negative quarters
NET SALES(HY) At USD 50.77 MM has Grown at -46.31%
OPERATING CASH FLOW(Y) Lowest at USD -175.07 MM
ROCE(HY) Lowest at -136.4%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -39.35%, its profits have fallen by -2242.5%

Underperformed the market in the last 1 year

Even though the market (S&P 500) has generated returns of 25.41% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -39.35% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is ARS Pharmaceuticals, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

ARS Pharmaceuticals, Inc.

-39.35%

0.09

67.49%

S&P 500

25.41%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

143.32%

EBIT Growth (5y)

-228.11%

EBIT to Interest (avg)

-63.34

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.20

Sales to Capital Employed (avg)

0.24

Tax Ratio

1.87%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

7.01

EV to EBIT

-3.64

EV to EBITDA

-3.67

EV to Capital Employed

-19.35

EV to Sales

7.75

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-150.01%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company

DEBT-EQUITY RATIO (HY)

Lowest at -170.36 %

-35What is not working for the Company

NET SALES(HY)

At USD 50.77 MM has Grown at -46.31%

OPERATING CASH FLOW(Y)

Lowest at USD -175.07 MM

ROCE(HY)

Lowest at -136.4%

RAW MATERIAL COST(Y)

Grown by 16.4% (YoY

CASH AND EQV(HY)

Lowest at USD 445.95 MM

INTEREST(Q)

Highest at USD 2.44 MM

OPERATING PROFIT(Q)

Lowest at USD -59.75 MM

PRE-TAX PROFIT(Q)

Lowest at USD -60.62 MM

NET PROFIT(Q)

Lowest at USD -60.62 MM

EPS(Q)

Lowest at USD -0.61

Here's what is working for ARS Pharmaceuticals, Inc.

Debt-Equity Ratio

Lowest at -170.36 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for ARS Pharmaceuticals, Inc.

Net Sales

At USD 50.77 MM has Grown at -46.31%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Pre-Tax Profit

At USD -60.62 MM has Fallen at -41.4%

over average net sales of the previous four periods of USD -42.87 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -60.62 MM has Fallen at -41.47%

over average net sales of the previous four periods of USD -42.85 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Interest

At USD 2.44 MM has Grown at inf%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Operating Cash Flow

Lowest at USD -175.07 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Interest

Highest at USD 2.44 MM

in the last five periods and Increased by inf% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Operating Profit

Lowest at USD -59.75 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit

Lowest at USD -60.62 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -60.62 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD -0.61

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Cash and Eqv

Lowest at USD 445.95 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost

Grown by 16.4% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales